Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adaptimmune Ther ADR (ADAP)

Adaptimmune Ther ADR (ADAP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 256,698
  • Shares Outstanding, K 246,825
  • Annual Sales, $ 60,280 K
  • Annual Income, $ -113,870 K
  • 60-Month Beta 2.33
  • Price/Sales 4.26
  • Price/Cash Flow N/A
  • Price/Book 10.53
Trade ADAP with:

Options Overview Details

View History
  • Implied Volatility 73.44% ( -156.45%)
  • Historical Volatility 62.80%
  • IV Percentile 12%
  • IV Rank 6.91%
  • IV High 903.08% on 12/01/23
  • IV Low 11.81% on 06/11/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 227
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 14,835
  • Open Int (30-Day) 14,195

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.17
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +38.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9601 +8.32%
on 06/04/24
1.3400 -22.39%
on 05/16/24
-0.1300 (-11.11%)
since 05/13/24
3-Month
0.8721 +19.25%
on 04/18/24
1.6500 -36.97%
on 03/28/24
-0.5500 (-34.59%)
since 03/13/24
52-Week
0.4200 +147.62%
on 11/28/23
2.0500 -49.27%
on 03/08/24
+0.0300 (+2.97%)
since 06/13/23

Most Recent Stories

More News
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysisInterim analysis data reinforces the potential...

ADAP : 1.0400 (unch)
Adaptimmune Reports Q1 2024 Financial and Business Updates

Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024Commercial and manufacturing infrastructure...

ADAP : 1.0400 (unch)
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approvalPhiladelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile...

ADAP : 1.0400 (unch)
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...

ADAP : 1.0400 (unch)
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchiseUpdate on afami-cel launch plans to be provided at the April 18th...

ADAP : 1.0400 (unch)
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...

ADAP : 1.0400 (unch)
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024Confirmatory evidence for afami-cel full approval agreed with...

ADAP : 1.0400 (unch)
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ:...

ADAP : 1.0400 (unch)
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with...

ADAP : 1.0400 (unch)
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and Oxford,...

ADAP : 1.0400 (unch)

Business Summary

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 1.0833
2nd Resistance Point 1.0667
1st Resistance Point 1.0533
Last Price 1.0400
1st Support Level 1.0233
2nd Support Level 1.0067
3rd Support Level 0.9933

See More

52-Week High 2.0500
Fibonacci 61.8% 1.4273
Fibonacci 50% 1.2350
Fibonacci 38.2% 1.0427
Last Price 1.0400
52-Week Low 0.4200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar